摘要
目的:研究头孢哌酮/他唑巴坦(Cefperazone/tazobactam CFP/TAZ 4:1)体外抗菌活性。方法:临床分离致病菌601株,经Vitek或API系统鉴定到种,用Nitrocephin纸片法测试各菌β-内酰胺酶及Vitek—506卡测定超广谱β-内醚胺酶(ESBL)。采用琼脂中板二倍稀释法测定最低抑菌浓度(MIC);试管二倍稀释法测定最低杀菌浓度(MBC)并绘制杀菌曲线;测试细菌接种量,培养基pH和血清蛋白含量对MIC的影响。结果:头孢哌酮/他唑巴坦4:1配比对产 ESBL菌株的 MIC50和 MIC90分别比单头孢哌酮低 32-64倍及 16-32倍,低于头孢哌酮/舒巴坦(CFP/SBT)和哌拉西林/他唑巴坦(PIP/TAZ)2倍和4倍,本品杀菌活性强于单头孢哌酮,但与头孢哌酮/舒巴坦1:1和哌拉西林/他唑巴坦8:1基本一致,细菌接种量、培养基pH和血清蛋白含量对本品抗菌活性影响小。结论:CFP/TAZ 4:1是一个有效的β-内酰胺酶的复合制剂,有进一步研究开发价值。
OBJECTIVE: The antibacterial activity in vitro of cefperazone/tazobactam was evaluated. METHODS: Cefperazone/tazobactam (4:1) against 601 clinical isolated strains was compared with cefperazone, tazobactam, cefperazone/sulbactam, piperacillinltazobactam and impipenenilceilastatin. Minimal inhibitory concentrations (MIC) were measured by agar dilution method and minimal bactericidal concentrations (MBC) were measured by broth dilution method. RESULTS: The antibacterial activity of cefperazone/tazobactam (4:1), the MIC50 and MIC90 against the strains producing extended spectrum b-lactamases (ESBLs) were 32-64 times and 16-32 times lower than cefperazone and were 2 times and 4 times lower than cefperazone/sulbactam and piperacillin/tazobactam. The bactericidal activity of cefperazone/tazobactam is better than cefperazone and similar as cefperazone/ sulbactam (1:1) and piperacillin/tazobactam (8:1). The inoculum size, pH and concentration of serum protein did not influence the in vitro the activity of cefperazone/tazobatam (4:1). CONCLUSION: Cefperazone/tazobactam (4:1) is an effective antibiotic containing β-lactamases inhibitor and valuable to be investigated.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2001年第6期410-414,共5页
The Chinese Journal of Clinical Pharmacology